MedPath

Neurofeedback and Nomophobia in Young Adults

Phase 4
Conditions
Biofeedback
Anxiety
Interventions
Other: Neurofeedback
Other: Health education
Registration Number
NCT06188910
Lead Sponsor
University of Salamanca
Brief Summary

Introduction: Given the growing increase in addiction to social networks and smartphone use in young people and its implications for health, it is necessary to investigate effective interventions for the appropriate use of these technologies and coping with possible signs of addiction.

Objective: To evaluate the effect of an intervention based on neurofeedback techniques on anxiety and other disorders associated with problematic use of mobile phones and the internet in young adults.

Methodology: Randomised controlled clinical trial with two parallel groups: an intervention group (IG) and a control group (CG). The study population will be young adults aged 18-30 years. A sample size of 36 participants has been estimated, 18 in each group to detect a difference of 3.9 points or more on the DASS-21 anxiety questionnaire.

All participants will receive an educational workshop on the responsible use of new technologies and the promotion of healthy lifestyles. The IG, in addition to this educational workshop, will receive 20 neurofeedback sessions during 8 weeks, 2-3 sessions/week with the MUSE neurofeedback device.

A baseline and 3-month post-intervention assessment will be conducted for both groups to study change variables related to smartphone addiction (Smartphone Addiction Scale-Short Version (SAS-SV)), nomophobia (Nomophobia Questionnaire (NMP-Q)), depression, anxiety and stress (Depression, Anxiety and Stress Scale 21-item (DASS-21)) and sleep quality.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Have one or more mobile devices such as smartphones.
  • Have a compatible mobile device to install and use the Muse: EEG Meditation & Sleep application.
  • Be fully functional.
  • Willingness to voluntarily participate in the study and sign the informed consent form.
Exclusion Criteria
  • History of severe psychiatric disorders (such as schizoaffective disorders, bipolar disorder, major depressive episode with symptoms or other non-organic psychotic disorders) requiring psychiatric treatment in the 6 months prior to study entry.
  • History of brain injury or other problems contraindicating the use of neurofeedback.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NeurofeedbackNeurofeedback3 weekly 30-minute neurofeedback sessions per week for 12 weeks
ControlHealth educationHealth education, a 25-minute session, on mobile phone addiction and promotion of healthy lifestyles
Primary Outcome Measures
NameTimeMethod
AnxietyBaseline, 3-months

Anxiety evaluated through Depression, Anxiety and Stress Scale 21-item (DASS-21). Minimum 0 - maximum 63

Secondary Outcome Measures
NameTimeMethod
NomophobiaBaseline, 3-months

Nomophobia evaluated through Nomophobia Questionnaire (NMP-Q). Minimum 20 - maximum 140

Sleep QualityBaseline, 3-months

Sleep quality evaluated through Atenas questionnaire. Minimum 0 - maximum 24

Trial Locations

Locations (1)

University of Salamanca

🇪🇸

Salamanca, Spain

© Copyright 2025. All Rights Reserved by MedPath